Rchr
J-GLOBAL ID：201801000207825334
Update date: Dec. 26, 2022
Okuda Hiroyuki
オクダ ヒロユキ | Okuda Hiroyuki
Contact this researcher
You can send email directly to the researcher.
Affiliation and department：
社会医療法人恵佑会札幌病院 腫瘍内科
About 社会医療法人恵佑会札幌病院 腫瘍内科
Search "社会医療法人恵佑会札幌病院 腫瘍内科"
Job title：
部長
Research field (1)：
Hematology and oncology
Papers (3)：
Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2018. 30. 2. 259-265
MiuraY, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, et al. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). Gastric cancer. 21. 1. 84-95
Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, et al. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer. 21. 5. 792-801
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM
